Deerfield Private Design Fund IV, L.P. (CIK 1680307) reported 11 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-03-02). Recent activity: Buy LRMR (1.1M shares), Buy LRMR (1.1M shares), Buy LRMR (831,978 shares), Buy LRMR (2.0M shares), Sell NUVL (371,287 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 1.1M | $5.4M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 1.1M | $5.4M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 831,978 | $4.2M |
| 2026-03-02 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 2.0M | $10.0M |
| 2025-11-24 | Nuvalent, Inc. (NUVL) | Director | Sell | 371,287 | $35.4M |
| 2025-11-24 | Nuvalent, Inc. (NUVL) | Director | Sell | 371,287 | $35.4M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 3.4M | $10.8M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 3.4M | $10.8M |
| 2025-08-04 | Larimar Therapeutics, Inc. (LRMR) | Director | Buy | 2.6M | $8.3M |
| 2025-07-01 | ARS Pharmaceuticals, Inc. (SPRY) | Insider | Sell | 370,075 | $6.8M |
| 2025-07-01 | ARS Pharmaceuticals, Inc. (SPRY) | Insider | Sell | 370,074 | $6.8M |
Source: SEC Form 4 filings · as of 2026-03-02